Entering text into the input field will update the search result below

Amarin Corporation plc's (AMRN) CEO Karim Mikhail on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Amarin Corporation plc (NASDAQ:AMRN) Q2 2021 Earnings Conference Call August 5, 2021 7:30 AM ET

Company Participants

Michael Kalb - Chief Financial Officer

Karim Mikhail - President and Chief Executive Officer

Conference Call Participants

Ken Cacciatore - Cowen

Yasmeen Rahimi - Piper Sandler

Louise Chen - Cantor Fitzgerald

Dennis Ding - Jefferies Group LLC

Jessica Fye - J.P. Morgan


Welcome to Amarin Corporation's conference call to discuss its Second Quarter and Six Months 2021 Financial Results and Operational Updates. This conference call is being recorded today, August 5, 2021.

I would like to turn the conference call over to Michael Kalb, Chief Financial Officer at Amarin.

Michael Kalb

Good morning, everyone, and thank you for joining us. Turning to Slide 2 of the presentation accompanying today's call, which can be found in the Investor Relations section of our website at www.AmarinCorp.com. Please be aware that this conference will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act.

Examples of such statements include, but are not limited to - these statements are based on information available to us today, August 5, 2021. We may not achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements.

We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.

For additional information concerning the factors that could cause actual results to differ materially, please see the Risk Factors section of our quarterly

Recommended For You

Comments (2)

LRNMO25 profile picture
Like the PFE involvement! Clearly PFE is not promoting Vascepa just to help AMRN.
LRNMO25 profile picture
So glad Thero is gone. Karim is exactly what AMRN needed. Upwards now. Patience will now pay off!
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.